Exact Sciences Corp. (Nasdaq: EXAS), a leading provider of cancer screening and diagnostic tests, today announced that the ...

The Cologuard Plus test demonstrated 95% sensitivity for colorectal cancer detection at 94% specificity, making it the most ...

The updated stool test for colon cancer finds more cancers and has fewer false positives, meaning fewer people need follow-up ...

Exact Sciences has launched its new "Cologuard Plus" test. This test is gaining attention as the most accurate non-invasive ...

Cologuard is getting an upgrade after 10 years on the market, as Exact Sciences starts to roll out the new version of its ...

Exact Sciences (EXAS) announced the launch of Cologuard Plus, which it calls “the most accurate noninvasive colorectal cancer screening test ...

The dog signs off on a distinctly potty-mouthed note: “So, come on: Pick up your s*** and let’s f*** colon cancer,” it says ...

Guggenheim analyst Subbu Nambi lowered the firm’s price target on Exact Sciences (EXAS) to $60 from $73 and keeps a Buy rating on the shares.

Exact Sciences Corporation’s EXAS investment in high-return pipeline opportunities with significant patient impacts should drive growth in the upcoming quarter. Additionally, the company is advancing ...

A month has gone by since the last earnings report for Exact Sciences (EXAS). Shares have lost about 10.6% in that time frame, underperforming the S&P 500. Will the recent negative trend continue ...

EXACT Sciences Corp. is a molecular diagnostics company, which focuses on the early detection and prevention of colorectal cancer. It developed Cologuard, a screening test for the early detection ...

Learn more about whether Alvotech or Exact Sciences Corporation is a better investment based on AAII's A+ Investor grades, ...